Mutant KRAS is a druggable target for pancreatic cancer

Pancreatic ductal adenocarcinoma (PDA) represents an unmet therapeutic challenge. PDA is addicted to the activity of the mutated KRAS oncogene which is considered so far an undruggable therapeutic target. We propose an approach to target KRAS effectively in patients using RNA interference. To meet t...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Zorde Khvalevsky, Elina, Gabai, Racheli, Rachmut, Itzhak Haim, Horwitz, Elad, Brunschwig, Zivia, Orbach, Ariel, Shemi, Adva, Golan, Talia, Domb, Abraham J., Yavin, Eylon, Giladi, Hilla, Rivkin, Ludmila, Simerzin, Alina, Eliakim, Rami, Khalaileh, Abed, Hubert, Ayala, Lahav, Maor, Kopelman, Yael, Goldin, Eran, Dancour, Alan, Hants, Yael, Arbel-Alon, Sagit, Abramovitch, Rinat, Shemi, Amotz, Galun, Eithan
Format: Artigo
Langue:Inglês
Publié: National Academy of Sciences 2013
Sujets:
Biological Sciences
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3870687/
https://ncbi.nlm.nih.gov/pubmed/24297898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1314307110
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires